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Summary
Autosomal dominant periodic fevers are characterized
by intermittent febrile attacks of unknown etiology and
by recurrent abdominal pains. The biochemical and mo-
lecular bases of all autosomal dominant periodic fevers
are unknown, and only familial Hibernian fever (FHF)
has been described as a distinct clinical entity. FHF has
been reported in three families—the original Irish-Scot-
tish family and two Irish families with similar clinical
features. We have undertaken a genomewide search in
these families and report significant multipoint LOD
scores between the disease and markers on chromosome
12p13. Cumulative multipoint linkage analyses indicate
that an FHF gene is likely to be located in an 8-cM
interval between D12S77 and D12S356, with a maxi-
mum LOD score (Z max) of 3.79. The two-point Z max
was 3.11, for D12S77. There was no evidence of genetic
heterogeneity in these three families; it is proposed that
these markers should be tested in other families, of dif-
ferent background, that have autosomal dominant pe-
riodic fever, as a prelude to identification of the FHF-
susceptibility gene.
Introduction
Autosomal dominant periodic fever was first described
by Bouroncle and Doan (1957), who reported a family
in which abdominal pain and fever occurred in six sib-
ships over five generations. Since then, dominant inher-
itance of periodic fever has been reported in several eth-
nic groups—for example, Austrians (Mache et al. 1996),
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Dutch (Zweers and Erkelens 1993) Finns (Karenko et
al. 1992), Germans (Gertz et al. 1987; Hawle et al.
1989), Italians (Reich and Franklin 1970), Swiss (Fed-
erspiel and Tonz 1987), and Swedes (Bergman et al.
1968). However, only familial Hibernian fever (FHF) has
been described as a separate clinical entity, originally in
an Irish-Scottish family based in the United Kingdom
(Williamson et al. 1982; McDermott et al. 1997) and
subsequently in two Irish families with a similar clinical
presentation (Quane et al. 1997). FHF is one of at least
three hereditary-periodic-fever syndromes that are char-
acterized by recurrent attacks of abdominal pain and
fever and that may be associated with musculoskeletal
manifestations (Kastner 1997); the other two genetic
syndromes are familial Mediterranean fever (FMF)
(Meyerhoff 1980) and hyperimmunoglobulinemia D
(hyper-IgD syndrome) (Van der Meer et al. 1984). Al-
though FHF clinically resembles FMF, the inheritance in
FHF is dominant rather than recessive; the duration of
attacks is generally longer, and there is a favorable re-
sponse to high-dose steroids (McDermott et al. 1996).
Amyloidosis, which is a major cause of morbidity in
FMF without colchicine prophylaxis, appears to be rel-
atively rare in FHF. The prevalence of FHF is unknown
but is probably much lower than that of FMF; rates as
high as 1/250 and 1/1,000 have been reported for FMF,
in Iraqi and Sephardic Jews, respectively (Kastner 1997).
A high index of suspicion is necessary to allow diagnosis
of FHF; the age at onset and the clinical severity are
variable, but disease usually occurs at !40 years of age.
The FMF gene, designated “MEFV,” has beenmapped
to the short arm of chromosome 16 (16p13.3) in Jewish
and Armenian families (Pras et al. 1992; Shohat et al.
1992), as well as in Arabs, Druze Moslems, and Turks
(Aksentijevich et al. 1993). The FMF-susceptibility gene
(pyrin/marenostrin) recently has been identified as a
member of the RoRet gene family (French FMF Con-
sortium 1997; International FMF Consortium 1997),
and missense mutations in exon 10 of this gene are
thought to be responsible for the condition. To date, no
susceptibility loci have been mapped for FHF, but X-
linked inheritance is excluded, since there are at least
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Figure 1 Pedigrees of the three families studied. To facilitate drawing of the pedigrees, not all family members have been included.
four cases of father-son transmission in the original FHF
family. Linkage of FHF toMEFV has also been excluded
(McDermott et al., in press). We have initiated a genome
screen in the three families described above and report
evidence for a susceptibility gene(s) localized to chro-
mosome 12p13.
Subjects and Methods
Clinical Evaluation
The project was subject to hospital-ethical-committee
approval in each participating center, and informed con-
sent was obtained from all participating family mem-
bers. Clinical history was ascertained for all available
living family members, through interview, medical re-
cords, and examination. Affection statuswas determined
by application of criteria described elsewhere (Mc-
Dermott et al. 1997). Two cardinal signs and at least
one minor criterion were required for a definite diagnosis
of FHF. The major criteria were (i) recurrent febrile at-
tacks with no other identifiable cause and (ii) either re-
current abdominal pains or localizedmyalgias associated
with marked stiffness during febrile episodes. Minor cri-
teria consisted of (i) discrete tender erysipelas-like skin
lesions found anywhere during an attack, (ii) conjunc-
tival injection, (iii) periorbital edema, (iv) positive family
history (autosomal dominant), and (v) benefit from high-
dose prednisolone in !72 h. Individuals fulfilling some
criteria but fewer than two major and one minor were
treated as unknowns for the purposes of linkage analysis.
Families.—The original extended family (family A) in
which FHF was described and the two Irish families
(families B and C) (fig. 1) with affected members ful-
filling the criteria for FHFwere studied. There werex16
known affected individuals in five sibships over three
generations in family A, with 4 instances of male-to-
male transmission. In family B there were 8 definitely
affected individuals and 3 possibly affected (of a total
of 23), whereas there were 4 definitely affected members
among the 8 individuals studied in family C. Samples
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Figure 2 Schematic regional map of chromosome 12p. Markers
used for linkage analysis in this study are indicated, and their respective
distances (v) are given (Kucherlapati et al. 1997). Marker D12S314
was used in the study by Mulley et al. (1997) but was not used in the
present study.
were not taken from children !10 years of age. Clinical
features, including pedigrees and laboratory data per-
taining to these families, have been described elsewhere
(Williamson et al. 1982; McDermott et al. 1997; Quane
et al. 1997)
Search strategy and microsatellite-analysis genotyp-
ing.—Genomic DNA was extracted from peripheral
blood by use of Puregene kits (Gentra Systems). For the
purpose of genome screening, the Medical Research
Council (MRC) mapping set of 200 fluorescently labeled
markers defining a 10-cM resolution was used initially.
Our strategy involved concentration on candidate-gene
regions, and PCR primers were chosen from these
regions, for simple-tandem-repeat–polymorphism am-
plification. PCR reactions were performed in a 10-ml
volume containing 1 ml (∼10 ng) DNA in 1# Taq poly-
merase buffer (10 mMTris-HCl pH 8.3, 2.0 mMMgCl2,
200mM each dNTP, 50 mM KCl, and 0.1% Triton-X
100) containing 10 pmol of each primer and 0.25 units
of Taq polymerase (Promega). A 96-well PTC100 MJR
thermal cycler machine (M.J. Research) was used for
PCR amplification by a touchdown protocol. The fol-
lowing is a brief resume of the protocol: denaturation
at 94C for 45 s, followed by touchdown annealing at
various temperatures (descending progressively from
60C to 46C) for 45 s, with extension at 72C for
45 s. The touchdown annealing temperatures were de-
creased by 3C intervals, to 48C, after every third cycle,
and 14 cycles were then performed at 46C (Don et al.
1991). Genotypings were performed by means of an Ap-
plied Biosystems (ABI) 373A automated DNA sequencer
and 6.0% Sequagel 6 nondenaturing acrylamide (Na-
tional Diagnostics). For electrophoretic multiplexing, an
average of three to five were combined per lane, and
allele sizes were calculated on the basis of an internal
size standard in each lane (Genescan 350 or 500 Tamra;
Perkin Elmer ABI). Amplified fragments were analyzed
by Genescan and Genotyper software (Perkin Elmer
ABI) on a Macintosh Quandra 650. It was usually nec-
essary to dilute the final PCR product to one-fifth, after
assessment on a 1% agarose gel, before the ABI loading
for analysis. Additional pairs of fluorescently labeled
primers were purchased commercially (PE-ABI) for chro-
mosome 12p13–region markers, to obtain comprehen-
sive coverage (Weissenbach et al. 1992; Gyapay et al.
1994). All genotypings were scored blinded to pheno-
type and, in the case of uncertainty about allele size,
were performed at least twice. Allele classification and
frequencies were taken from published sources (Ge´ne´-
thon database).
Linkage Analysis
Two-point LOD scores between the disease locus and
each individual marker were calculated by the MLINK
program of the LINKAGE 5.2 package (Lathrop et al.
1985), by the U.K. Human Genome Mapping Project
(HGMP) Resources Centre and FASTLINK, version 3.0
(Cottingham et al. 1993). A dominant-transmission
model was specified, with age-specific penetrances of
10%, 70%, and 90% for individuals in age groups !15
years, 15–40 years, and 1 40 years, respectively. The
probability of a normal homozygote being diagnosed as
affected was set at .001 for each age group (to allow for
the possibility of phenocopies), and the frequency of the
abnormal allele was set at .00001 (in view of the relative
rarity of the disease). Recombination frequency (v) was
assumed to be equal for males and females. Homoge-
neity testing was performed by the program HOMOG
(Terwilliger and Ott 1994). This analysis evaluates ev-
idence for interfamilial genetic heterogeneity by com-
paring a likelihood including interfamilial heterogeneity
versus a likelihood assuming homogeneity. The analysis
was conducted by use of all two-point results frommark-
ers in the region. Sequential five-point multipoint anal-
ysis was performed by VITESSE (O’Connell and Weeks
1995), and results were plotted contiguous to each other
(Terwilliger and Ott 1994, pp. 126–134). Marker order
and intermarker distances were based on existing linkage
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Figure 3 Multipoint linkage analysis between FHF and markers
on chromosome 12p13 (D12S364, D12S358, D12S77, D12S356,
D12S99, D12S93, D12S314, and D12S100), determined by the use of
genotypes from all three families. Marker D12S356 was set at map
position zero.
Table 1
Cumulative Two-Point LOD Scores for Chromosome 12p Markers Spanning the
FHF Locus in the Three Families Studied
MARKER
LOD SCORE AT RECOMBINATION FRACTION OF
Zmax vmax.00 .01 .05 .10 .15 .20
D12S364 19.99 8.83 3.99 2.04 1.08 .53
D12S358 .92 .61 2.22 2.72 2.78 2.63 2.79 .13
D12S77 4.29 1.72 2.64 3.11 3.11 2.89 3.15 .13
D12S356 .44 .64 1.94 2.34 2.32 2.11 2.36 .11
D12S99 1.03 1.00 .92 1.13 1.32 1.33 1.38 .19
D12S93 7.90 3.35 .77 .17 .55 .67 .68 .22
maps. The markers that were studied and the distances
among them are given in figure 2 (Krauter et al. 1995;
Kucherlapati et al. 1997). Haplotype analysis was also
performed, to determine whether there was haplotype
sharing between affected individuals within and between
families.
Results
We had excluded approximately one-third of the ge-
nome (as containing the FHF gene), using 78 markers
over nine specific chromosomes, when a pairwise posi-
tive LOD score was found for D12S358, on chromo-
some 12p13, in family A (maximum LOD score [Zmax]
 3.93 at maximum v [vmax]  .00). We have tested a
total of 14 markers on the short arm of chromosome
12 (fig. 2). The FHF candidate region included six mark-
ers between and including D12S364 and D12S93 (i.e.,
markers D12S364, D12S358, D12S77, D12S356,
D12S99, and D12S93), in all three families. Table 1
shows the cumulative two-point LOD scores for these
six markers spanning the FHF candidate region. The
two-point Zmax in the three families was at D12S77 (Zmax
 3.11 at v  .12) (fig. 3). The two-point Zmax in in-
dividual families peak at D12S358, in family A (Zmax 
3.93 at vmax  0), at D12S356 in family B (Zmax  1.90
at vmax  0), and at D12S77 and D12S356 in family C
(Zmax 0.56 at vmax 0). Results from homogeneity tests
showed no significant evidence for heterogeneity, for any
of the markers tested in this region. Additional alleles
were seen for all categorized markers—D12S364 (16
alleles, instead of the reported 14), D12S358 (13 instead
of 11), D12S77 (14 instead of 13), D12S356 (10 instead
of 9), and D12S99 (12 instead of 10), and D12S93 (9).
Additional alleles were assigned frequencies of .02, and
known alleles were proportionately reduced in fre-
quency, to enable total frequencies to equal unity.
For the multipoint analysis, the following map order
was used: D12S364-(.05)-D12S358-(.07)-D12S77-
(.08)-D12S356-(.02)-D12S99-(.02)-D12S93 (Krauter et
al. 1995; Kucherlapati et al. 1997). Multipoint analysis
with the complete set of markers spanning the disease
interval was not possible, because of the high number
of alleles per marker. Results from sequential five-point
analysis are depicted in figure 2. Multipoint analyses
revealed that the FHF gene was most likely to lie in the
8-cM interval between markers D12S77 and D12S356
(Zmax  3.79). However, the 2-cM interval between
D12S99 and D12S93 also provided strong support for
linkage (Zmax 3.46) and cannot be excluded as possibly
containing the FHF gene. The 1-LOD support interval,
therefore, includes ∼10 cM. Intermarker distances were
consistent with the published map. Different estimates
of disease-allele frequencies did not significantly alter the
LOD scores. Haplotype analysis for polymorphic mark-
ers in 12p13 did not reveal any association between the
FHF locus and a particular haplotype (data not shown).
Discussion
We have used linkage analysis to map the locus/loci
for autosomal dominant FHF. The data reported here
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show tight linkage between FHF and polymorphic mi-
crosatellite markers from the centromeric region of chro-
mosome 12p. During the course of this analysis, Mulley
et al. (1997) described a multipoint LOD score of 6.14
at D12S356 in an unspecified number of “benign peri-
odic fever” families (symbolized as “FPF,” for “familial
periodic fever”). They concluded that an FPF gene was
located in the interval between D12S314 and D12S364,
spanning an ∼19-cM interval on the short arm of chro-
mosome 12 (Mulley et al. 1997). Although no clinical
details are available on the family material used, it ap-
pears that the conditions of FHF and FPF are genetically
similar, since LOD scores are significantly positive for
the same markers in both sets of families. Assuming that
the same gene is present in the families that we have
studied, then, we have further narrowed the critical in-
terval, to ∼8–12 cM. There remains the possibility of
more than one susceptibility gene being involved, es-
pecially since two-point LOD scores maximize at mark-
ers 15 cM apart in the two larger families; alternatively,
the result may be due a phenotype error in one of the
families. Family C is too small to produce significant
independent LOD scores in the absence of a larger num-
ber of markers, but preliminary data also support the
possibility that this region is involved.
The current interval is very gene-rich site, and many
candidate genes for FHF have already been mapped to
the region, including genes with immune function, such
as TNFRRP, CD4, and CD69 (Kucherlapati et al. 1997).
Identification of the FMF gene has provided insight into
the possible mechanism of unexplained fevers, and we
therefore are also looking for MEFV homologues and
genes with functional similarities in the linkage area.
Despite the similarities in the symptoms and clinical fea-
tures present in FHF and FMF, it remains to be proved
that affected individuals are indeed suffering from sim-
ilar categories of disease. All three families studied share
Irish ancestry, but, as far as we are aware, they are un-
related, and, indeed, the grandmother, who appears to
have been the carrier in family A, originally came from
Scotland. We have not identified an ancestral chromo-
some with the markers used in this study, as has been
the case for a subset of families suffering from FMF
(Aksentijevich et al. 1993); this is compatible with the
independent occurrence of mutations at the FHF locus
in different populations and families. Our priority is to
identify additional markers, from within the region, that
may define an ancestral haplotype shared by two ormore
families and also to clarify the reason for the 15-cM
distance between peak LOD scores in the families. Fur-
ther narrowing of the linkage interval will be achieved
by fine mapping, prior to our embarking on a “posi-
tional candidate cloning project” approach. The other
immediate objective is to test these markers in European
families with autosomal dominant periodic fever—but
not specifically FHF—to detect whether genetic heter-
ogeneity is a feature of this group of conditions.
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